Giovanni Rezza - Infectious Diseases

Author Information

Giovanni Rezza is a distinguished researcher affiliated with the Department of Infectious, Parasitic and Immune-Mediated Diseases at the Istituto Superiore di Sanità in Rome, Italy. His research primarily focuses on infectious diseases, particularly in understanding and combating the spread of viral infections, such as SARS-CoV-2, which has been central to the COVID-19 pandemic. His work is crucial in public health for devising strategies to control and mitigate infectious diseases, especially through vaccination and epidemiological studies.

Research Contributions

Giovanni Rezza has made significant contributions to research on the SARS-CoV-2 virus, examining the effectiveness of mRNA vaccines, the impact of viral variants, and the public health response to the COVID-19 pandemic in Italy. His studies include analyzing the genomic characteristics of the virus, vaccine coverage, and breakthrough infections in vaccinated populations. Furthermore, Rezza's work extends to addressing vaccine shortages and evaluating immunization coverage during the pandemic, which are vital for forming effective public health policies.

Aliases

Giovanni Rezza is also known by the aliases G Rezza and G. Rezza. These variations of his name may appear in different publications and databases.

Publication and Citation Metrics

Metric	Value
Citation Count	24,626
H-index	70
Number of Papers	644

Publications:

Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study

DOI: 10.1136/bmj-2021-069052

Year: 2022

COVID-19 response: effectiveness of weekly rapid risk assessments, Italy

DOI: 10.2471/blt.20.286317

Year: 2022

Are vaccine shortages a relevant public health issue in Europe? Results from a survey conducted in the framework of the EU Joint Action on Vaccination.

DOI: 10.1016/j.vaccine.2022.02.041

Year: 2022

A SARS-CoV-2 Outbreak Among Nursing Home Residents Vaccinated with a Booster Dose of mRNA COVID-19 Vaccine

DOI: 10.1007/s10900-022-01082-8

Year: 2022

Analysis of Genomic Characteristics of SARS-CoV-2 in Italy, 29 January to 27 March 2020

DOI: 10.3390/v14030472

Year: 2022

Childhood Immunisation Coverage during the COVID-19 Epidemic in Italy

DOI: 10.3390/vaccines10010120

Year: 2022

Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021

DOI: 10.2807/1560-7917.ES.2022.27.5.2100429

Year: 2022

First detection of SARS-CoV-2 lineage A.27 in Sardinia, Italy.

DOI: 10.4415/ANN_22_01_01

Year: 2022

Evolution of SARS-CoV-2 IgG Seroprevalence in Children and Factors Associated with Seroconversion: Results from a Multiple Time-Points Study in Friuli-Venezia Giulia Region, Italy

DOI: 10.3390/children9020246

Year: 2022

Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the Delta variant in Italy, 19 July to 12 December 2021.

DOI: 10.1080/14760584.2022.2064280

Year: 2022

What is respiratory hygiene and why is it important?

Why is Awareness Important?

How Do B Cells Recognize Pathogens?

What is the Future of Malaria Control and Eradication?

What are Immunodeficiency Disorders?

What Are Respiratory Droplets?

Can the Inflammatory Response be Modulated?

What are the Treatment Options for Fatigue in Infectious Diseases?

How Does Genomic Sequencing Impact Clinical Practice?

What Happens After the Throat Swab is Collected?

Partnered Content Networks

Relevant Topics